Mineralys Therapeutics (MLYS) Aandelenoverzicht
Mineralys Therapeutics, Inc. is een biofarmaceutisch bedrijf dat medicijnen ontwikkelt tegen ziekten die worden veroorzaakt door ontreguleerd aldosteron in de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
MLYS Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Mineralys Therapeutics, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$29.85 |
| 52 Week Hoogtepunt | US$47.65 |
| 52 Week Laag | US$12.59 |
| Bèta | 0.48 |
| 1 maand verandering | 8.51% |
| 3 maanden verandering | 3.18% |
| 1 Jaar Verandering | 87.03% |
| 3 jaar verandering | 112.00% |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | 61.88% |
Recent nieuws en updates
Recent updates
Mineralys: 'Hold' As Hypertension OSA Data Barely Delivers And AstraZeneca On The Move
Summary Mineralys is downgraded from 'Strong Buy' to 'Hold' due to competitive and clinical setbacks. MLYS's lorundrostat NDA was accepted by the FDA with a PDUFA date of December 22, 2026, targeting uncontrolled/resistant hypertension. Failure to meet the primary endpoint in the OSA hypertension subpopulation and AstraZeneca's earlier PDUFA for baxdrostat create significant headwinds. MLYS remains well-capitalized, with cash runway into 2028 and further ATM capacity, but faces execution and competitive risks. Read the full article on Seeking Alpha
Regulatory And Competitive Pressures Will Challenge Hypertension Launch Yet Longer Term Potential Remains
Catalysts About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor for adults with uncontrolled or resistant hypertension and related comorbidities. What are the underlying business or industry changes driving this perspective?
Hypertension PDUFA Decision And Large Target Population Will Support Strong Long Term Opportunity
Catalysts About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor for patients with uncontrolled and resistant hypertension. What are the underlying business or industry changes driving this perspective?
Hypertension And Cardiorenal Catalysts Will Reshape Long Term Prospects For This Biotech
Catalysts About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor, for patients with uncontrolled and resistant hypertension and related cardiorenal conditions. What are the underlying business or industry changes driving this perspective?Will Mineralys Therapeutics (NASDAQ:MLYS) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts
Summary Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met with statistical significance. Upcoming catalysts include the full data release from Advance-HTN in March 2025 and phase 2 Explore-CKD trial results in Q2 2025. Financially, company has $198.2 million in cash but may need to raise funds soon, potentially diluting shareholders. The Anti-Hypertensive drugs market worldwide is expected to reach $22.41 billion by 2025. Read the full article on Seeking AlphaIs Mineralys Therapeutics (NASDAQ:MLYS) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension
Summary I believe Mineralys Therapeutics has a promising candidate with Lorundrostat for hypertension, CKD, and OSA. It should report more key pivotal clinical data this year. MLYS has several Phase 2 and 3 trials on Lorundrostat that could position it favorably for a potential FDA submission by late 2026 or sometime in 2027. According to the company’s slides, Lorundrostat seems to have superior selectivity in some patients that reduces cortisol suppression and other side effects. My main concern with MLYS is its relatively short cash runway. But still, I think it has enough runway to fund its key trials through 2025. Overall, I feel MLYS is a good speculative “Buy” at these levels, especially after a substantial pullback in the shares with promising catalysts lined up in 2025. Read the full article on Seeking AlphaHere's Why We're Not Too Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning
Summary Mineralys' lorundrostat, a selective aldosterone synthase inhibitor, shows promise in treating resistant hypertension with fewer side effects compared to current MRAs. Upcoming catalysts include pivotal phase 2 and 3 trial results in 2025, with significant potential market impact if successful. Despite a solid cash position, further funding may be needed for regulatory stages, making acquisition by a major player a strategic move. Given its potential and current valuation, I recommend a cautious buy for Mineralys at these prices. Read the full article on Seeking AlphaWe're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Mineralys Therapeutics: A Story To Keep An Eye On
Summary Today, we look at Mineralys Therapeutics, a clinical-stage biotechnology company focused on developing treatments for diseases driven by elevated aldosterone levels. The company's sole asset, lorundrostat, is an aldosterone synthase inhibitor that has shown promising results in Phase 2 trials for the treatment of uncontrolled hypertension. Mineralys is conducting two additional trials for lorundrostat and is also evaluating its potential for the treatment of hypertension in patients with chronic kidney disease. A full investment analysis follows in the paragraphs below. Read the full article on Seeking AlphaMineralys: 2nd Half 2024 Hypertension Data Readout
Summary Mineralys Therapeutics, Inc. has two ongoing studies evaluating use of lorundrostat for the treatment of patients with uncontrolled or resistant hypertension; these are ADVANCE-HTN and LAUNCH-HTN. Results from the phase 3 ADVANCE-HTN study using lorundrostat for the treatment of patients with uncontrolled or resistant hypertension, expected in the 2nd half of 2024. Mineralys is also conducting a phase 2 study for the use of lorundrostat in treating hypertension in Chronic Kidney Disease patients, with results expected in the first half of 2024 or Q1 2025. The global hypertension market is expected to reach $43.18 billion by 2030. Read the full article on Seeking AlphaWe're Hopeful That Mineralys Therapeutics (NASDAQ:MLYS) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Rendement voor aandeelhouders
| MLYS | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 9.0% | 1.2% | 1.1% |
| 1Y | 87.0% | 34.6% | 28.7% |
Rendement versus industrie: MLYS overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 34.6 % opleverde.
Rendement versus markt: MLYS overtrof de US markt, die het afgelopen jaar een rendement opleverde van 28.7 %.
Prijsvolatiliteit
| MLYS volatility | |
|---|---|
| MLYS Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: MLYS heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van MLYS is het afgelopen jaar gedaald van 15% naar 9%.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2019 | 76 | Jon Congleton | mineralystx.com |
Mineralys Therapeutics, Inc. is een biofarmaceutisch bedrijf dat geneesmiddelen ontwikkelt tegen ziekten die worden veroorzaakt door ontreguleerd aldosteron in de Verenigde Staten. Het ontwikkelt lorundrostat, een eigen, oraal toegediende, zeer selectieve aldosteronsynthaseremmer voor de behandeling van cardiore aandoeningen die worden beïnvloed door ontreguleerd aldosteron, zoals hypertensie, chronische nierziekte en obstructieve slaapapneu. Het bedrijf was voorheen bekend als Catalys SC1, Inc. en veranderde zijn naam in Mineralys Therapeutics, Inc. in mei 2020.
Mineralys Therapeutics, Inc. Samenvatting
| MLYS fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$2.46b |
| Inkomsten(TTM) | -US$151.78m |
| Inkomsten(TTM) | n/a |
Is MLYS overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| MLYS resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$0 |
| Kosten van inkomsten | US$0 |
| Brutowinst | US$0 |
| Overige uitgaven | US$151.78m |
| Inkomsten | -US$151.78m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -1.84 |
| Brutomarge | 0.00% |
| Nettowinstmarge | 0.00% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde MLYS op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/24 20:27 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Mineralys Therapeutics, Inc. wordt gevolgd door 9 analisten. 8 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Umer Raffat | Evercore ISI |
| Richard J. Law | Goldman Sachs |